These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 33161492)

  • 1. Efficacy and Safety of Once Weekly Dulaglutide in East Asian Patients with Type 2 Diabetes: Subgroup Analysis by Potential Influential Factors.
    Ma J; Zhang B; Hou J; Peng Y
    Diabetes Ther; 2021 Jan; 12(1):211-222. PubMed ID: 33161492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Once-Weekly Dulaglutide in Elderly Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN Studies.
    Kuang J; Zhu J; Liu S; Li Q
    Diabetes Ther; 2020 Oct; 11(10):2329-2339. PubMed ID: 32857293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.
    Yu M; Yuan GY; Zhang B; Wu HY; Lv XF
    Diabetes Ther; 2020 May; 11(5):1147-1159. PubMed ID: 32277401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic Safety of Once-Weekly Dulaglutide in Chinese Patients with Type 2 Diabetes Mellitus: Subgroup Analysis by Potential Influencing Factors.
    Zhou Y; Zhu J; Wu H; Deng Y; Ji Q
    Diabetes Ther; 2021 Oct; 12(10):2677-2690. PubMed ID: 34453682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Dulaglutide Versus Insulin Glargine in Chinese T2DM Patients: A Subgroup Analysis of a Randomized Trial (AWARD-CHN2).
    Li Y; Li L; De Peng Y; Song GY; Ye SD; Du LY; Hou JN; Ji QH
    Diabetes Ther; 2019 Aug; 10(4):1435-1452. PubMed ID: 31228090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Dulaglutide in Chinese Patients with Type 2 Diabetes and Different Glycemic Patterns: a Post-hoc Analysis of the Phase 3 AWARD-CHN2 Trial.
    Li Q; Zhang Q; Wang R; Hong T
    Diabetes Ther; 2022 Jan; 13(1):161-173. PubMed ID: 34870792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of Dulaglutide as a First Injectable Option for Patients with Type 2 Diabetes: A Post-Hoc Pooled Analysis.
    Patel H; Munir K; Sutherland S; Karanikas CA; Konig M
    Diabetes Ther; 2019 Dec; 10(6):2321-2330. PubMed ID: 31605302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Once-Weekly Dulaglutide in Type 2 Diabetes Patients Using Insulin: Exploratory Subgroup Analysis by Insulin Regimen.
    Onishi Y; Ishii H; Oura T; Takeuchi M
    Diabetes Ther; 2020 Mar; 11(3):735-745. PubMed ID: 31994009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.
    Davidson JA; Manghi FP; Yu M; Linetzky B; Landó LF
    Endocr Pract; 2016 Dec; 22(12):1406-1414. PubMed ID: 27540883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subgroup Analysis Stratified by Baseline Pancreatic β-cell Function in a Japanese Study of Dulaglutide in Patients with Type 2 Diabetes.
    Iwamoto N; Matsui A; Kazama H; Oura T
    Diabetes Ther; 2018 Feb; 9(1):383-394. PubMed ID: 29264713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
    Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Dulaglutide Monotherapy Compared to Glimepiride in Oral Antihyperglycemic Medication-Naïve Chinese patients with Type 2 Diabetes: A Post Hoc Analysis of AWARD-CHN1.
    Li YM; Zhang LH; Li XJ; Zhang B; Hou JN; Tong NW
    Diabetes Ther; 2020 May; 11(5):1077-1090. PubMed ID: 32219675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.
    Bi Y; Lu S; Tang J; Du L; Ji L
    Diabetes Ther; 2024 May; 15(5):1125-1137. PubMed ID: 38494574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of Characteristics of Gastrointestinal Adverse Events with Once-Weekly Dulaglutide Treatment in Chinese Patients with Type 2 Diabetes: A Post Hoc Pooled Analysis of Two Randomized Trials.
    Guo L; Zhang B; Hou J; Zhou Z
    Diabetes Ther; 2020 Aug; 11(8):1821-1833. PubMed ID: 32621083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS programme).
    Kiyosue A; Dunn JP; Cui X; Hickey A; Hirase T; Imaoka T; Heine RJ
    Diabetes Obes Metab; 2023 Apr; 25(4):1056-1067. PubMed ID: 36545807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between weight change and glycaemic control in patients with type 2 diabetes receiving once-weekly dulaglutide treatment.
    Umpierrez GE; Pantalone KM; Kwan AY; Zimmermann AG; Zhang N; Fernández Landó L
    Diabetes Obes Metab; 2016 Jun; 18(6):615-22. PubMed ID: 26969812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1).
    Wysham C; Blevins T; Arakaki R; Colon G; Garcia P; Atisso C; Kuhstoss D; Lakshmanan M
    Diabetes Care; 2014 Aug; 37(8):2159-67. PubMed ID: 24879836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weight loss in patients with type 2 diabetes receiving once-weekly dulaglutide plus insulin lispro or insulin glargine plus insulin lispro: A post-hoc analysis of the AWARD-4 study across baseline body mass index subgroups.
    Fuechtenbusch M; Aberle J; Heitmann E; Nicolay C; Jung H
    Diabetes Obes Metab; 2019 Jun; 21(6):1340-1348. PubMed ID: 30737891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Change in HbA
    Gentilella R; Romera I; Nicolay C; Buzzetti R; Vázquez LA; Sesti G
    Diabetes Ther; 2019 Jun; 10(3):1113-1125. PubMed ID: 31055780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.